COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Management of Supraventricular Tachycardia of Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03528616
Recruitment Status : Unknown
Verified May 2018 by Mona Hussien, Assiut University.
Recruitment status was:  Not yet recruiting
First Posted : May 18, 2018
Last Update Posted : May 18, 2018
Information provided by (Responsible Party):
Mona Hussien, Assiut University

Brief Summary:
• Supraventricular tachycardia (SVT) is defined as an abnormally rapid heart rhythm originating above the ventricles. It usually has narrow complex tachycardia but this is not always the case. Conventionally, atrial flutter and fibrillation are excluded from this group.ventricular tachycardia is the most common rhythm disturbance seen in children.(2) Most general practitioners will deal with a case at some point. While in most cases ventricular tachycardia can be considered a benign rhythm disorder, special consideration needs to be given to infants, athletes and patients with Wolff-Parkinson-White syndrome.

Condition or disease Intervention/treatment
Supraventricular Tachycardia Drug: adenosine,Propranolol,flecainide, amiodarone, propranolol, digoxin and procainamide.

Show Show detailed description

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 50 participants
Observational Model: Case-Crossover
Time Perspective: Prospective
Target Follow-Up Duration: 1 Year
Official Title: Management of Supraventricular Tachycardia of Children Admitted to Assiut University Children Hospital(Clinical Audit)
Estimated Study Start Date : May 15, 2018
Estimated Primary Completion Date : April 30, 2019
Estimated Study Completion Date : November 30, 2019

Resource links provided by the National Library of Medicine

Intervention Details:
  • Drug: adenosine,Propranolol,flecainide, amiodarone, propranolol, digoxin and procainamide.
    drugs used for treatment of supraventricular tachycardia

Primary Outcome Measures :
  1. Evaluate management of SVT in the cardiology unit of Assiut University Children Hospital according to international guidelines by using pharmacological and non pharmacological treatments. [ Time Frame: one year ]

    Descriptive sheet of the study checklist that will be asked about in all cases: Clinical examination and ECG at presentation,Physical maneuvers(vagal stimulation),Drug therapy including:adenosine and other antiarrythmic drugs as Flecainide,propranolol,amiodarone,digoxin and verapamil.

    Appropriate dose of drugs,Putting on monitor ECG during treatment,Synchronized DC cardioversion in hemodynamically unstable cases.

    Yes ,No ,℅ of the folowing, Clinical examination and ECG at presentation Vagal manoeuvers,diving reflex,One side carotid massage,Valsalva manoeuvre Drug therapy Adenosine only,Flecainide only,Propranolol and Amiodarone,Amiodarone only Digoxin only,Digoxin then Amiodarone, Verapamil Maintain ECG monitoring,Synchronized DC cardioversion. These data will be collected and revised to show how would doctors in the cardiology unit of Assiut University Children Hospital manage SVT according to the international guinternational guidelines.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Month to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
prospective observational study

Inclusion Criteria:

  • Cases of SVT who will be admitted to Assiut University Children hospital during the period between May,2018 to May,2019.

Exclusion Criteria:

  • newborns up to one month age
Additional Information:

Layout table for additonal information
Responsible Party: Mona Hussien, principal investigator, Assiut University Identifier: NCT03528616    
Other Study ID Numbers: SVT
First Posted: May 18, 2018    Key Record Dates
Last Update Posted: May 18, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Tachycardia, Supraventricular
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Cardiac Conduction System Disease
Pathologic Processes
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Vasodilator Agents
Cardiotonic Agents
Enzyme Inhibitors
Protective Agents
Sensory System Agents
Peripheral Nervous System Agents
Purinergic P1 Receptor Agonists
Purinergic Agonists